Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

131I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study

  • Ma, Jun (Department of Interventional Radiology, Zhongshan Hospital, Fudan University) ;
  • Wang, Jian-Hua (Department of Interventional Radiology, Zhongshan Hospital, Fudan University)
  • Published : 2015.12.03
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This study evaluated the safety and objective response of combining $^{131}I$-labeled-metuximab (Licartin) with transarterial chemoembolization (TACE) in the treatment of unresectable hepatocellular carcinoma (HCC). Materials and Methods: In a multicenter open-label clinical trial, 341 enrolled patients with stage III/IV HCC according to TNM criteria were nonrandomly assigned to a trial group (n=167) and a control group (n=174), undergoing TACE following hepatic intra-arterial injection of licartin or TACE alone from July 2007 to July 2009. Radiopharmaceutical distribution was evaluated. The primary endpoint was overall survival; secondary endpoints included time-to-progression (TTP), toxicity and adverse events (AEs). Results: The radiobiological distribution demonstrated better localization of licartin in liver tumors than other tissues (P<0.01). The organ absorbed doses to liver and red marrow were $3.19{\pm}1.01Gy$ and $0.55{\pm}0.22Gy$, respectively. The 1-year survival rate was significantly higher [79.47% vs. 65.59%, hazard ratio (HR), 0.598, P=0.041] and TTP significantly improved ($6.82{\pm}1.28$ vs. $4.7{\pm}1.14months$, P=0.037) compared with the control group. Patients at stage III achieved more benefit of one year survival than stage IV in the trial group (86.9% vs. 53.8%, P<0.001). There were significant different toxicities in leukocytopenia, thrombocytopenia and increased total bilirubin level [P<0.001, P=0.013, P<0.01, relative risk (RR) 1.63, 1.33, 1.43], but no differences in severe AEs of upper GI hemorrhage and severe liver dysfunction between the groups (5.39% vs. 2.3%, P=0.136). Conclusions: Owing to excellent tumor-targeting, promised efficacy and favourable toxicity profile, the novel combination therapy of licartin and TACE could be applied in patients with unresectable HCC.

Keywords

References

  1. Aitken KL, Hawkins MA (2014). The role of radiotherapy and chemoradiation in the management of primary liver tumours. Clin Oncol (R Coll Radiol), 26, 569-80. https://doi.org/10.1016/j.clon.2014.05.016
  2. Alloni D, Cutaia C, Mariotti L, Friedland W, Ottolenghi A (2014). Modeling dose deposition and DNA damage due to low-energy $\beta$(-) emitters. Radiat Res, 182, 322-30. https://doi.org/10.1667/RR13664.1
  3. Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011). Management of hepatocellular carcinoma: an update. AASLD practice guideline. Hepatol, 53, 1020-2. https://doi.org/10.1002/hep.24199
  4. Chen ZN, Mi L, Xu J, et al (2006). Targeting radioimmunotherapy of hepatocellular carcinoma with iodine ($^{131}I$) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys, 65, 435-44. https://doi.org/10.1016/j.ijrobp.2005.12.034
  5. Chiesa C, Mira M, Maccauro M, et al (2012). A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging, 56, 503-8.
  6. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer (2012). EASL-EORTC clinical practice guidelines: management of hepatocellulcer carcinoma. J Hepatol, 56, 908-43. https://doi.org/10.1016/j.jhep.2011.12.001
  7. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
  8. Goldenberg DM, Sharkey RM (2006). Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Imaging, 50, 248-64.
  9. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  10. Jiang W, Zeng ZC (2013). Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma? Oncol, 84, 69-74. https://doi.org/10.1159/000345893
  11. Juweid ME, Zhang CH, Blumenthal RD, et al (1997). Factors influencing hematologic toxicity of radioimmunotherapy with $^{131}I$-labeled anti-carcinoembryonic antigen antibodies. Cancer, 80, 2749-53. https://doi.org/10.1002/(SICI)1097-0142(19971215)80:12+<2749::AID-CNCR55>3.0.CO;2-8
  12. Kassis AI, Adelstein SJ (2005). Radiobiologic principles in radionuclide therapy. J Nucl Med, 46, 4-12.
  13. Lambert B, Van de Wiele C (2005). Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Mol Imaging, 32, 980-9. https://doi.org/10.1007/s00259-005-1859-z
  14. Lau WY, Lai EC, Leung TW, Yu SC (2008). Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trialupdate on 5-year and 10-year survival. Ann Surg, 247, 43-8. https://doi.org/10.1097/SLA.0b013e3181571047
  15. Lencioni R, Crocetti L (2012). Local-regional treatment of hepatocellular carcinoma. Radiol, 262, 43-58. https://doi.org/10.1148/radiol.11110144
  16. Llovet JM, Di Bisceglie AM, Bruix J, et al (2008). Design and endpoints of clinical trials in hepatocellualr carcinoma. J Natl Cancer Inst, 100, 698-711. https://doi.org/10.1093/jnci/djn134
  17. Ministry of Health of the People's Republic of China (2011). Diagnosis, management and treatment of hepatocellular caricnoma (V2011). J Clin Heptol, 27, 1141-59.
  18. Pinter M, Hucke F, Graziadei I, et al (2012). Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiol, 263, 590-9. https://doi.org/10.1148/radiol.12111550
  19. Salem R, Mazzaferro V, Sangro B (2013). Yttrium 90 radioembolization for the treatment of hepatocellular caricinoma: biological lessons, current challenges, and clinical perspectives. Hepatol, 58, 2188-97. https://doi.org/10.1002/hep.26382
  20. Sgouros G (2005). Dosimetry of internal emitters. J Nucl Med, 46, 18-27.
  21. Wu L, Yang YF, Ge NJ, et al (2012). Hepatic artery injection of $^{131}I$-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. Eur J Nucl Med Mol Imaging, 39, 1306-15. https://doi.org/10.1007/s00259-012-2145-5
  22. Xu J, Shen ZY, Chen XG, et al (2007b). A randomized controlled trail of licartin for preventing hepatoma recurrence after liver transplantation. Hepatol, 45, 269-76. https://doi.org/10.1002/hep.21465
  23. Xu J, Xu HY, Zhang Q, et al (2007a). HAb18G/CD147 functions in invasion and metastasis of hepatocelluar carcinoma. Mol Cancer Res, 5, 605-14. https://doi.org/10.1158/1541-7786.MCR-06-0286
  24. Zanzonico PB, Divgi C (2008). Patient-specific radiation dosmetry for radionuclide therapy of liver tumors with intrahepatic artery rhenium-188 lipiodol. Semin Nucl Med, 38, 30-9. https://doi.org/10.1053/j.semnuclmed.2007.10.005
  25. Zeng ZC, Tang ZY, Liu KD, et al (1998). Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with combination of surgery and intrahepatic arterial infusion of $^{131}I$-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol, 124, 275-80. https://doi.org/10.1007/s004320050166
  26. Zhang Z, Bian H, Feng Q, et al (2006). Biodistribution and localization of iodine-131 labeled metuximab in patients with hepatocellular caricinoma. Cancer Biol Ther, 5, 318-22. https://doi.org/10.4161/cbt.5.3.2431

Cited by

  1. reinforces antitumor activity of metuximab by reversing epithelial-mesenchymal transition via VEGFR-2 signaling in hepatocellular carcinoma vol.23, pp.1, 2017, https://doi.org/10.1111/gtc.12545